Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) EBIT (2020 - 2025)

Rapid Micro Biosystems' EBIT history spans 6 years, with the latest figure at -$12.2 million for Q4 2025.

  • On a quarterly basis, EBIT fell 19.38% to -$12.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.4 million, a 5.06% increase, with the full-year FY2025 number at -$47.4 million, up 5.06% from a year prior.
  • EBIT hit -$12.2 million in Q4 2025 for Rapid Micro Biosystems, down from -$11.4 million in the prior quarter.
  • Over the last five years, EBIT for RPID hit a ceiling of -$9.7 million in Q1 2021 and a floor of -$17.3 million in Q4 2022.
  • Historically, EBIT has averaged -$13.2 million across 5 years, with a median of -$12.8 million in 2024.
  • Biggest five-year swings in EBIT: tumbled 80.67% in 2021 and later rose 29.39% in 2023.
  • Tracing RPID's EBIT over 5 years: stood at -$14.6 million in 2021, then dropped by 18.58% to -$17.3 million in 2022, then increased by 29.39% to -$12.2 million in 2023, then rose by 16.07% to -$10.2 million in 2024, then dropped by 19.38% to -$12.2 million in 2025.
  • Business Quant data shows EBIT for RPID at -$12.2 million in Q4 2025, -$11.4 million in Q3 2025, and -$12.1 million in Q2 2025.